Research programme: protein phosphatase magnesium-dependent 1 inhibitors - Antisoma/The Institute of Cancer ResearchAlternative Names: PPM1D inhibitors - Antisoma
Latest Information Update: 15 Jun 2011
At a glance
- Originator Antisoma; The Institute of Cancer Research
- Mechanism of Action Protein phosphatase 2C inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 20 May 2010 Antisoma is looking for a licensing partnership for the programme
- 07 Oct 2008 Preclinical trials in Cancer in United Kingdom (unspecified route)